Cytokine release syndrome caused by immune checkpoint inhibitor: a case report

doi:10.16352/j.issn.1001-6325.2022.11.1764

Abstract

Abstract: Objective To investigate the diagnosis and treatment of cytokine release syndrome (CRS) caused by immune checkpoint inhibitor(ICI). Methods A case of ICI pembrolizumab leading to CRS was analyzed in Department of Pulmonary and Critical Care Medicine of Peking Union Medical College Hospital. ResultsA 52-year-old woman with advanced adenosquamous lung cancer developed fever and hypotension after receiving pembrolizumab. Results of laboratory test showed an obviously increased serum ferritin, C response protein, interleukin-6 and abnormal liver function. Without positive infectious results, she was ultimately diagnosed as CRS. The patient was treated with steroids and tocilizumab with good clinical response. Conclusions CRS caused by ICIs develops rapidly and lead to severe results. It is important to consider CRS in patient who developed systemic inflammatory response syndrome after ICIs. Steroids combined tocilizumab is a potential choice of treatment.

Key words: immune checkpoint inhibitor, cytokine release syndrome, systemic inflammatory response syndrome, lung cancer

CLC Number:

R734.2

SI Xiao-yan, WANG Han-ping, ZHANG Li, WANG Meng-zhao, ZHANG Xiao-tong. Cytokine release syndrome caused by immune checkpoint inhibitor: a case report[J]. Basic & Clinical Medicine, 2022, 42(11): 1764-1766.

0
/ / Recommend

Add to citation manager EndNote|Reference Manager|ProCite|BibTeX|RefWorks

URL: http://journal11.magtechjournal.com/Jwk_jcyxylc/EN/10.16352/j.issn.1001-6325.2022.11.1764

http://journal11.magtechjournal.com/Jwk_jcyxylc/EN/Y2022/V42/I11/1764

References 7

[1]	Tay SH, Toh MMX, Thian YL, et al. Cytokine release syndrome in cancer patients receiving immune checkpoint inhibitors: a case series of 25 patients and review of the literature[J]. Front Immunol, 2022,13:807050. doi: 10.3389/fimmu.2022.807050.
[2]	Ceschi A, Noseda R, Palin K, et al. Immune checkpoint inhibitor-related cytokine release syndrome: analysis of WHO global pharmacovigilance database[J]. Front Pharmacol, 2020,11:557. doi: 10.3389/fphar.2020.00557.
[3]	Bone RC, Balk RA, Cerra FB, et al. Definitions for sepsis and organ failure and guidelines for the use of innovative therapies in sepsis. The ACCP/SCCM Consensus Confer-ence Committee. American College of Chest Physicians/Society of Critical Care Medicine[J]. Chest, 1992,101:1644-1655.
[4]	Ciner AT, Hochster HS, August DA, et al. Delayed cytokine release syndrome after neoadjuvant nivolumab: a case report and literature review[J]. Immunotherapy, 2021,13:1071-1078.
[5]	Rotz SJ, Leino D, Szabo S, et al. Severe cytokine release syndrome in a patient receiving PD-1-directed therapy[J]. Pediatr blood cancer, 2017,64:e26642. doi: 10.1002/pbc.26642.
[6]	Sackstein P, Zaemes J, Kim C. Pembrolizumab-induced cytokine release syndrome in a patient with metastatic lung adenocarcinoma: a case report[J]. J Immunother Cancer, 2021,9:e002855. doi: 10.1136/jitc-2021-002855.
[7]	Yomota M, Mirokuji K, Sakaguchi M, et al. Cytokine release syndrome induced by immune-checkpoint inhibitor therapy for non-small-cell lung cancer[J]. Intern Med (Tokyo, Japan), 2021,60:3459-3462.

[1]	GAN Zi-ying, TANG Hui. Research progress of oncolytic virus combined with PD-1/PD-L1 inhibitors [J]. Basic & Clinical Medicine, 2022, 42(4): 651-655.
[2]	ZHANG Jian, ZHANG Ji-jiong. LncRNA UNC5B-AS1 targeting miR-339-5p regulates the proliferation and apoptosis of human lung adenocarcinoma cell line A549 [J]. Basic & Clinical Medicine, 2022, 42(3): 454-460.
[3]	PAN Rui-li, MA Qian-hui, XU Yan, WANG Meng-zhao, WANG Su-e, GUAN Yu-xia. Mediating effect of hope level between depression and psychological resilience in patients with advanced lung cancer [J]. Basic & Clinical Medicine, 2022, 42(2): 291-295.
[4]	YANG Ye, DANG Rong-guang, ZHANG Jing, DONG Chao, SONG Xue-jing. Correlation of expression of lncRNA ZFAS1 and hsa-miR-372-3p in lung cancer tissues with the malignant characteristics and prognosis of patients [J]. Basic & Clinical Medicine, 2022, 42(12): 1861-1866.
[5]	HE Shao-bo, LUO Fu-hua, JIANG Chuan-ming, LIU Xuan-mei. Salidroside inhibits the proliferation and epithelial mesenchymal transformation of NSCLC cell by negatively regulation of TACC2 expression [J]. Basic & Clinical Medicine, 2022, 42(11): 1681-1689.
[6]	LIANG Bing, YAN Yu-lan. rL-RVG inhibits the proliferation and migration of human small cell lung cancer cell line NCI-H446 [J]. Basic & Clinical Medicine, 2022, 42(10): 1549-1554.
[7]	JIANG Xue-dong, LI Wen-ya. Erastin induces cell apoptosis in human non-small cell lung cancer cell line A549 [J]. Basic & Clinical Medicine, 2021, 41(9): 1313-1317.
[8]	ZHANG Ruo-xi, HAN Bing. Progress of immune checkpoint inhibitors for the treatment of myelodysplastic syndrome [J]. Basic & Clinical Medicine, 2021, 41(8): 1210-1215.
[9]	WAN Xue-qiong, CHEN Jia, HE Chao, YE Xing-ming. Zerumbone inhibits the proliferation, migration and invasion of human non-small cell lung cancer cell line A549 through up-regulating FBXW7 expression [J]. Basic & Clinical Medicine, 2021, 41(8): 1163-1168.
[10]	LIU Xi-bang, ZHU Lin-zhi, JIAO De-min, TANG Xia-li, CHEN Jun, HU Xu-gang, CHEN Qing-yong. Anlotinib combined with chloroquine induces apoptosis of human non-small cell lung cancer cell line H1299 [J]. Basic & Clinical Medicine, 2021, 41(7): 1018-1023.
[11]	REN Meng-xian, LIANG Wei, LIU Yan. Effects of celecoxib combined with IMRT on immune function and serum tumor markers in elderly patients with advanced non-small cell lung cancer [J]. Basic & Clinical Medicine, 2021, 41(6): 890-894.
[12]	HAN Yan, GUAN Bing-qi, ZHOU Gang, MA Fei. Predictive value of Xiaoyan decoction combined with GC chemotherapy in the treatment of advanced non-small cell lung cancer based on DWI [J]. Basic & Clinical Medicine, 2021, 41(5): 661-666.
[13]	XU Fei, CHEN Wei-da, GUO Ming-hao, CHEN Ze-tao. Progress of ferroptosis mechanism and application in lung cancer therapy [J]. Basic & Clinical Medicine, 2021, 41(3): 442-447.
[14]	ZHAO Xiao-long, DAI Xiao-yan, MAO Cheng-yi, XIAO Hua-liang, WANG Dong, DAI Nan. Plasma exosomal APE1 expression of NSCLC patients is related to the sensitivity of platinum chemotherapy [J]. Basic & Clinical Medicine, 2021, 41(2): 165-170.
[15]	JIANG Yan-fang, TAN Li, XIANG Hua-hua, WEN Xiao-sha, GUO Zi-fen. Construction and optimization of detection technology platform for EGFR gene exon 19 del18bp mutation [J]. Basic & Clinical Medicine, 2021, 41(10): 1491-1496.